Soluble Fas gene therapy protects against Fas-mediated apoptosis of hepatocytes but not the lethal effects of Fas-induced TNF-α production by Kupffer cells

Cell Death and Differentiation

Volumn 9, Issue 6, 2002, Pages 626-635

  Matsuki, Y ^a   Li, L ^a   Hsu, H C ^a   Yang, P A ^a   Zheng, R ^b   Edwards, C K ^c   Chaudry, I H ^b   Zhang, H G ^a,d   Mountz, J D ^a,d  

^a The University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c AMGEN INC   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Apoptosis; Fas; Hepatocyte; Kupffer cells; TNF

Indexed keywords

ANTIBODY; FAS ANTIGEN; GADOLINIUM; GADOLINIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FAS ANTIBODY; LIVER ENZYME; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BLEEDING; BLOOD; C57BL MOUSE; ENZYMOLOGY; FEMALE; GENE THERAPY; GENETICS; HEPATITIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KUPFFER CELL; LIVER; LIVER CELL; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SOLUBILITY; ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; GENETIC TRANSFECTION; IN VIVO STUDY; LETHALITY; LIVER CELL DAMAGE; LIVER DISEASE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROVOCATION TEST; SURVIVAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; FEMALE; GADOLINIUM; GENE THERAPY; HEMORRHAGE; HEPATITIS; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; KUPFFER CELLS; LIVER; MALE; MICE; MICE, INBRED C57BL; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA; ANIMAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 85047698911     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401016     Document Type: Article

References (38)

1. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells
2. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome
3. Oxidized LDL activates fas-mediated endothelial cell apoptosis
4. Role of the liver in regulating numbers of circulating neutrophils
5. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation
6. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen
7. A novel domain within the 55 kd TNF receptor signals cell death
8. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis
9. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
10. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
11. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
12. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex
13. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
14. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
15. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus
16. Characterization of human Fas gene. Exon/intron organization and promoter region
17. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation
18. Lethal effect of the anti-Fas antibody in mice
19. Fas-mediated apoptosis in primary cultured mouse hepatocytes
20. Essential roles of the Fas ligand in the development of hepatitis
21. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis
22. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
23. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis
24. Apoptosis as a mechanism of tissue injury in liver allograft rejection
25. Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis
26. Serum levels of soluble Fas antigen in chronic hepatitis C patients
27. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus
28. Inhibition of Kupffer cells reduced CXC chemokine production and liver injury
29. Modulation of kupffer cell activity by gadolinium chloride in endotoxemic rats
30. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells
31. Fas- and tumor necrosis factor receptor 1-dependent but not perforin- dependent pathways cause injury in livers infected with an adenovirus construct in mice
32. Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver
33. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure
34. A simplified system for generating recombinant adenoviruses
35. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts
36. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor
37. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors
38. Role of Kupffer cells in interleukin-6 release following trauma- hemorrhage and resuscitation